Esparza et al. Vaccine, vol. 10 Issues 10 pp. 714-720, Oct 1992. |
A.S. Fauci, "Update on the Status of Vaccine Development," Pediatric Aids and HIV Infection: Fetus to Adolescent 5(1):47-58 (1994). |
Higgins et al., "MF59 Adjuvant Enhances the Immunogenicity of Influenza Vaccine in Both Young and Old Mice," Vaccine 14(6):478-484 (1996). |
Moore et al., "Immunization with a Soluble Recombinant HIV Protein Entrapped in Biodegradable Microparticles Induces HIV-Specific CD8.sup.+ Cytotoxic T Lymphocytes and CD4.sup.+ Th1 Cells," Vaccine 13(18):1741-1749 (1995). |
O'Hagan et al., "Biodegradable Microparticles for Oral Immunization," Vaccine 11:149-154 (1993). |
O'Hagan, "Recent Advances in Vaccine Adjuvants for Systemic and Mucosal Administration," J. Pharm. Pharmacol 49:1-10 (1997). |
Ott et al., "MF59--Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines," Vaccine Design: The Subunit and Adjuvant Approach (Powell, M.F. and Newman, M.J. eds.) Plenum Press, New York, pp. 277-296 (1995). |
Sanchez-Pescador et al., "The Effect of Adjuvants on the Efficacy of a Recombinant Herpes Simplex Virus Glycoprotein Vaccine," The Journal of Immunol. 141(5):1720-1727 (1988). |
Vordermeier et al., "Synthetic Delivery System for Tuberculosis Vaccines: Immunological Evaluation of the M. Tuberculosis 38 kDa Protein Entrapped in Biodegradable PLG Microparticles," Vaccine 13(16):1576-1582 (1995). |